Guilherme Perini, Hematologist at Israelita Albert Einstein Hospital, shared on X:
”2y-PFS of 80% in a ph2 will probably be a little bit less in the ph3.
Will it be practice changing? Im still trying to digest all data. Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.”
Title: Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial
Authors: Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua D. Brody, Daniel Morillo, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Yasmin H. Karimi, Catherine Thieblemont, Umberto Vitolo, Lori A. Leslie, Mayur S. Narkhede, Raúl Córdoba, Toshihiko Oki, Monica Wielgos-Bonvallet, Mina Khoshdeli, Yi Hao, Kimberly Archer, Malene Risum, David Belada.
You can also read ‘High-Dose Methotrexate Does Not Reduce CNS Relapse Risk in Ultra High-Risk LBCL: An International Analysis‘
